AI/ML Innovations Announces Completion of Share Issuance

• The most recent release (April 17, 2026) confirms the completion of a share issuance to settle outstanding indebtedness with service providers.
• Total shares issued: 17,118,420 common shares at a deemed price of Cdn$0.05 per share.
• The transaction is classified as a related party transaction where insiders received an aggregate of 11,848,000 shares (approximately 69% of the issuance).
• Regulatory exemption was granted under Multilateral Instrument 61-101 because the fair market value did not exceed 25% of the Company's market capitalization.
• A statutory hold period applies to these securities until August 18, 2026.
• Previous financing news (March 27, 2026) details a private placement of convertible debentures totaling $950,000 with insiders purchasing the majority ($550,000).
• Historical operational updates from late 2025 to early 2026 focus on pilot programs (Jamaica, Toronto Heart Centre, Movesense) and regulatory submissions rather than commercial revenue generation.

• The share issuance for debt settlement is dilutive to existing shareholders, increasing the total share count by approximately 6-7% based on estimated outstanding shares.
• Issuing shares at $0.05 when the market price is trading at $0.04 indicates a discount to current valuation and signals liquidity constraints where cash was unavailable for debt service.
• The high concentration of insider participation (11.8M shares) suggests management confidence but also concentrates voting power and potential future selling pressure upon hold period expiry in August 2026.
• While settling debt removes liabilities, the method (equity issuance) is generally viewed negatively by equity investors compared to cash repayment or convertible debt with longer maturities.
• The news aligns with previous financing activities (March debentures), indicating a continued reliance on capital markets for survival rather than organic revenue growth.

• Company: AI/ML Innovations Inc. operates through its subsidiary NeuralCloud Solutions Inc.
• Flagship Project: CardioYield™, an AI-powered Holter reporting platform powered by the MaxYield™ ECG signal-processing engine.
• Technology Focus: The company aims to convert biometric data into actionable clinical insights, specifically focusing on cardiac diagnostics and heart-brain connections.
• Development Stage: Pre-revenue; currently in pilot phases with clinics (Toronto Heart Centre, Jamaica) and wearable partners (Movesense).
• Regulatory Status: Seeking Health Canada Class II clearance for software as a medical device; US Patent No. 12,465,266 granted for core signal-processing architecture.